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Table 1. Patients’ characteristics 
Patient no. Diagnosis FIGO stage Age Radiotherapy dose (Gy) Chemotherapy
1 Cervical cancer IB1 46 50.4 Fluorouracil+cisplatin
2 Cervical cancer IB1 35 50.4 Weekly cisplatin
3 Cervical cancer  IB1 60 50.4 Weekly cisplatin
4 Cervical cancer  IB1 51 50.4 Paclitaxel+carboplatin
5 Cervical cancer IB1 49 50.4 Paclitaxel+carboplatin
6 Cervical Cancer IIA 45 50.4 Etoposide+cisplatin
7 Cervical cancer  IIB 64 50.4 Paclitaxel+carboplatin
8 Cervical cancer  IIB 55 59.4 Paclitaxel+carboplatin
9 Endometrial cancer IA 56 50.4 Not done
10 Endometrial cancer  IA 63 50.4 Not done
11 Endometrial cancer IB 50 50.4 Not done
12 Endometrial cancer IIIC 38 50.4 Paclitaxel+carboplatinOxidative stress and plasma endotoxin















































































Fig. 1. Glutathione (GSH)/oxidized glutathione (GSSG) ratio during 












Fig. 2. Blood endotoxin level (A) and positive rate (B) in patient subjects during radiotherapy. Endotoxin was expressed as mean±standard 
error. Endotoxin level between baseline and at 5th week of treatment was statistically significant (p<0.05) according to the results of the t-test.
Table 2. Result of Korean version of  EORTC QLQ-C30 questionnaire at baseline and 5th week of radiotherapy
EORTC QLQ-C30 Baseline 5th week % change of baseline p-value*
Functioning scales 
  Global health status 54.17±4.81 37.5±4.54 -30.8 0.049
  Physical functioning 75.56±3.99 66.11±4.96 -12.5 0.164
  Role functioning 68.06±8.46 47.22±8.94 -30.6 0.111
  Emotional functioning 72.92±3.74 71.53±5.51 -1.9 0.833
  Cognitive functioning 76.39±4.98 68.06±5.27 -10.9 0.252
  Social functioning 68.06±7.28 56.94±8.82 -16.3 0.362
Symptom scales
†
  Fatigue 40.74±4.06 51.85±8.22 27.3 0.437
  Nausea/vomiting 8.33±3.31 30.56±8.18 266.7 0.019
  Pain 22.22±4.72 34.72±9.08 56.3 0.234
Single-item scales
†
  Dyspnea  22.22±6.22 33.33±9.08 50.0 0.328
  Insomnia 25.0±8.41 47.22±8.99 88.9 0.089
  Appetite loss 16.67±5.03 47.22±10.86 183.3 0.045
  Constipation 8.33±4.49 11.11±6.49 33.3 0.939
  Diarrhea 5.56±3.89 52.78±9.97 850.0 <0.001
  Financial difficulties 22.22±7.57 36.11±11.24 62.5 0.440
Values are presented as mean±standard error. 
EORTC, European Organization for Research and Treatment of Cancer; QLQ, quality of life questionnaire.
*p-value was determined by paired t-test between baseline and final treatment. 
†Scores range from 0 to 100, with a higher score representing 
a greater degree of symptoms. Oxidative stress and plasma endotoxin
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Fig. 3. The change in the level of endotoxin was associated significantly with nausea/vomiting (p=0.001; (A) arrow head: 3 patients overlapped), 
but not with diarrhea (p=0.196; (B) arrow: 2 patients overlapped). Endotoxin final-baseline, difference in the endotoxin values between final 
and baseline week; Nausea and vomiting severity, difference in the severity of nausea and vomiting between final and baseline week; Diarrhea 



































































































minimize	radiotherapy-related	adverse	events	and	to	improve	Oxidative stress and plasma endotoxin
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QoL	in	cancer	patients.
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